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Recent studies with human embryonic stem (hES) cells have
established new protocols for substantial generation of pancre-
atic progenitors from deﬁnitive endoderm. These ﬁndings add to
the efﬁcient derivation of deﬁnitive endoderm, which is con-
trolled by Wnt and Nodal pathways, and delineate a step forward
in the quest for alternative -cell sources. It also indicates that
critical reﬁning of the available strategies might help deﬁne a
universal protocol for pancreatic differentiation applicable to
several cell lines, therefore offering the possibility for transplan-
tation of immune-matched or patient-speciﬁc hES–derived
-cells. We appraise here the fundamental role that bone mor-
phogenetic protein, ﬁbroblast growth factor, and retinoid sig-
naling play during pancreas development, and describe a
fundamental emergence of their combination in recent studies
that generated pancreatic cells from hES cells. We ﬁnally enu-
merate some prospects that might improve further differentiation
of the progenitor cells into functional -cells needed in diabetes
cell therapy. Diabetes 59:2094–2101, 2010
Overview of embryonic pancreas development. The
regulation of pancreas development from the gut
endoderm is a complex process that involves a carefully
balanced interplay between several common signaling
pathways. Studies in several model organisms indicate
conservation of the main mechanisms of pancreas devel-
opment from lower to higher vertebrates (Table 1). Gas-
trulation in the developing embryo (E7.5 in mice) results
in the formation of three germ layers, namely the ecto-
derm, the endoderm, and the mesoderm. It appears that
these germ layers do not further develop in isolation from
each other, but signals emanate from one to pattern the
other and vice versa (1). Several structures temporally
participate in these early tissue interactions including the
notochord (2), the cardiac mesoderm, the septum trans-
versum mesenchyme and the lateral plate mesoderm (3),
the aortic endothelial cells and the vitelline veins (4), and
the developing pancreatic mesenchyme (5).
As far as the pancreas is concerned, speciﬁc growth and
differentiation factors released by adjacent tissues control
a set of transcription factors expression, resulting in the
patterning of the ventral and dorsal prepancreatic
endoderm. The initial interactions usually confer compe-
tence to respond to additional inductive signals that
establish organ determination and speciﬁcation at partic-
ular time points referred to as competence windows.
Although our present knowledge of extrinsic factors that
control patterning, proliferation, and differentiation cues
throughout the developing pancreas is not yet complete,
there is strong evidence emanating from all vertebrate
developmental models that complex spatio-temporal com-
binations of common signaling pathways are crucial for
appropriate speciﬁcation of pancreatic cell fates from the
endoderm (6–9). These involve, for instance, the hedge-
hog, Wnt, retinoid, and Notch pathways, as well as Activin/
bone morphogenetic protein (BMP), ﬁbroblast growth
factor (FGF), vascular endothelial growth factor (VEGF),
epidermal growth factor (EGF), and hepatocyte growth
factor (HGF) signal transductions.
An overview of the roles played in pancreas develop-
ment by the most relevant growth and differentiation
factors is summarized in Table 2. A detailed sequential
presentation is difﬁcult to address because many signaling
events are not clearly dissociated from each other, while
others function redundantly or intermittently at several
developmental stages. It is also worth noting that the
developmental effects elicited by these common signals
can vary signiﬁcantly according to the cell type being
stimulated or according to the stage of development when
the signal occurs. This level of complexity is further
enhanced by the interplay between transcription factors
that lie downstream of these extracellular stimuli and are
responsible for observed developmental features.
During the past two decennia, considerable progress
has been achieved in understanding pancreas embryogen-
esis thanks to the numerous genetic studies involved in
transcription factors. Most of them belong to the ho-
meobox domain, the paired-box, or the basic helix-loop-
helix families. The sequential expression of different
transcription factors that control pancreas development
has been extensively reviewed elsewhere (6–8,10). Only a
brief summary of their expression pattern is given in Fig.
1 with special focus on 1) the early pancreatic epithelial
cells, 2) the pancreatic endocrine progenitors, and 3) the
endocrine subtypes selection.
Efﬁcient deﬁnitive endoderm differentiation from
many human embryonic stem cell lines and protocols.
It is presently well recognized that attempts to generate
pancreatic cells from pluripotent cells should ﬁrst estab-
lish a deﬁnitive endoderm (DE) population as occurs in
vivo. Wnt and Nodal signals were identiﬁed as sufﬁcient to
induce DE from mouse and human embryonic stem (hES)
cells, but also from induced pluripotent stem (iPS) cells. In
this model, high concentrations of activin A (ActA) are
used to mimic the function of the endogenous endoderm
inducer Nodal (11). Beside the activation of this pathway,
initial treatment with Wnt3a or BMP4 was found to im-
prove the efﬁciency of DE induction by setting up a
transient mesendoderm progenitor population, especially
when cultures are performed in feeder cell-free conditions
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differentiation from embryonic stem (ES) cells, antago-
nists of this pathway (LY294002, Wortmanin) were also
included in some protocols, resulting in an increased
efﬁciency (14,15). In addition, supplementation of sodium
butyrate was found to support endoderm differentiation
when combined with ActA (16), though it remains unclear
how this chemical participates in the signaling network
required for the deﬁnitive endoderm.
The standard and modiﬁed protocols for DE induction
from ES cells allow for the derivation of at least 60–80%
cells that express the characteristic markers FOXA2,
SOX17, GSC, and CXCR4 (Table 3) but not the visceral
endoderm marker SOX7 (13,14,16–20). Whether the quest
for a universal -cell differentiation protocol is a desired
myth or an achievable reality, it appears clear from the
literature that combined Wnt3a and ActA treatments efﬁ-
ciently activate DE phenotype in a vast majority of hES
cell lines. In other words, the molecular events that lead
DE differentiation in vivo have been largely—if not com-
pletely—unraveled and implemented in vitro. Despite the
recently described differences in the response of hES cell
lines to differentiation cues (21), the variability and the
low success rate in the outcome of initial pancreas differ-
entiation protocols might ﬁrst of all reﬂect the lack of such
a universal developmentally based strategy that thor-
oughly reproduces in vivo events in the culture dish after
the DE stage.
Noggin and retinoids: key players in blocking in vitro
liver induction and favoring pancreas speciﬁcation
from deﬁnitive endoderm. When maintained in culture
without added growth factors or when transplanted under
the kidney capsule of immunocompromised mice, hES-
derived deﬁnitive endoderm cells could spontaneously
generate hepatocyte-like cells characterized by the expres-
sion of AFP, albumin (ALB) (Fig. 2A), or hepatocyte-
speciﬁc antigen (12,17,20). This tendency for hepatic
TABLE 1
Time scale of pancreas development in mouse and human
Organogenesis and differentiation
events Mouse Human
Fusion dorsal aortae E8 —
Mesenchyme condensation over dorsal
gut endoderm E9.5 E26
Endoderm evaginates in condensed
dorsal mesenchyme E9.5 E26
Endoderm evaginates in condensed
ventral mesenchyme E10 E32
First endocrine cells (insulin, glucagon) E9.5–10.5 E52
Gut rotation, contact, and fusion of
ventral and dorsal buds E12–13 E37–56
Branching morphogenesis, acinar
differentiation, distinct cellular
architecture, -cells ampliﬁcation E13–14 E70–90
Endocrine cells accumulation beside
ducts E14–18 E75
Endocrine coalescence and islets
formation E18 E91–105
Birth E22 E260–280
The major sequences of developmental processes are similar in
mouse and human embryonic pancreas. The striking difference
resides in the duration of each stage, which can vary by a factor of
5t o1 5 .
TABLE 2
Overview of growth and differentiation factors that participate in vertebrate pancreas development
Stages GDFs Sources Functions
Speciﬁcation (E8.5–9.5) Wnt Mesoderm Inhibit foregut, pancreas, and liver
Shh, Ihh, Dhh Endoderm Anti-pancreatic
Activin B, FGF2 Notochord Repress hedgehog, pro-pancreatic
(Dend)
FGF–BMP Cmes, LPM Pro-hepatic/anti-pancreatic (Vend)
Noggin Dmes Repress BMP (Dend), pro-pancreatic
RA LPM, Dmes Gut patterning, bud and Pdx1 induction
Expansion (E9.5–12.5) VEGF-A Dorsal aorta Pdx1, insulin, Ptf1a induction
FGF1–7-10 Pmes Epithelium proliferation, branching
GCG Alpha cell Induce early insulin cells
EGF, betacellulin Pepi Epithelium proliferation, pro-endocrine?
Differentiation (E12.5–E15.5) Delta, jagged Pnep Anti-endocrine, progenitor proliferation
Activin A, B Endocrine Anti-exocrine/pro-endocrine (via NGN3)
BMP4–5-7 — -cell differentiation?
TGFB1–2-3 Pepi, acini Pro-endocrine, islet architecture
RA Pmes Pro-endocrine (NGN3 induction)
HGF Pmes, pepi Pro-–cell
GDF11 (BMP11) Pepi Pro-endocrine (NGN3 regulation)
Follistatin Pmes Pro-exocrine/anti-endocrine
Wnt (7 members) Pmes Control proliferation?
Maintenance and function (E15.5) VEGF-A Islet Islet vessels, endothelial fenestration
GDF11 (BMP11) Acini Pro-endocrine?
HB-EGF Duct, islet Islet architecture?
EGF, betacellulin — -cell proliferation?
GCG, Glp1 -cells Pro-–cell, insulin synthesis
IHH Islet Pdx1 and insulin expression
Wnt — Postnatal pancreatic growth
Cmes, cardiac mesoderm; Dmes, dorsal mesenchyme; GCG, glucagon; GDF, growth differentiation factor; HB-EGF, heparin-binding
epidermal growth factor; IHH, Indian hedgehog; LPM, lateral plate mesoderm; Pepi, pancreatic epithelium; Pmes, pancreatic mesenchyme;
Pnep, pancreatic NGN3
 endocrine progenitor. Dend, dorsal endoderm; Vend, ventral endoderm.
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wherein hES-derived DE cells were exposed to BMP
and/or FGF, two growth factors implicated in embryonic
liver induction and speciﬁcation (13,20,22,23). The contri-
bution of these pathways was further demonstrated by the
treatment with BMP antagonist Noggin and FGF receptor
antagonist SU5402, leading to the complete abrogation of
hepatic gene expression from DE progenies that otherwise
was mainly composed of hepatocytes. As suggested from
animal studies, these experiments also indicated that FGF
did not function in the induction but essentially contrib-
uted to the ampliﬁcation of liver progenitors initially
induced by BMP signaling (20). Therefore, the molecular
signals elicited by BMP and FGF are the main factors
driving hepatocyte differentiation from hES-derived DE
cells.
In vivo, BMP activity generated by the adjacent meso-
derm–derived structures and operating in the ventral
endoderm is associated with hepatic induction during
early embryonic development. On the contrary, ventral
pancreas progenitors are located away from the midline
endoderm with active BMP signaling, whereas BMP inhi-
bition in the dorsal endoderm plays a crucial function in
the acquisition of a pancreatic fate (3,24). The requirement
for BMP antagonism is reverted after pancreas induction
since this organ requires BMP signaling later on for the
maintenance of Pdx1 expression and further differenti-
ation. This underscores the existence of a tight compe-
tence window and the versatile functions of growth
factors during development, which complicates their in
vitro implementation for directed differentiation of ES
cells (24).
Retinoic acid (RA) plays a crucial role shortly after
gastrulation in endoderm patterning and in the induction
of PDX1 expression by pancreas progenitors in several
organisms from Xenopus to humans, which indicates the
conservation of its activity during evolution (25–27). This
role for RA has already been evaluated during mouse and
human ES cell differentiation in vitro and has proven to be
relevant for the induction of pancreatic gene expression,
notably detectable levels of PDX1 (17,23,28–32).
In line with the in vivo recognized functions of these two
signaling pathways on pancreas induction, recent studies
have combined BMP inhibition (Noggin supplementation)
with retinoid signaling immediately after the DE induction
stage and succeeded in producing large amounts (up to
80%) of PDX1
 pancreas progenitor cells (Table 3),
(13,14,20). Concomitantly, the proportion of hepatocytes
that could be detected in these conditions was signiﬁ-
cantly reduced (Fig. 2A and B), indicating an efﬁcient
blockade of their induction upon BMP antagonism (20,33).
This combination was efﬁcient not only in different hES
cell lines, but also in iPS cells (14), suggesting that the
basic molecular events that should be monitored in order
to design a universal pancreatic differentiation protocol
are being progressively clariﬁed. These minimally include
the signals for the blockade of hepatic induction on the
one hand and those required for pancreatic induction
(namely PDX1 expression) on the other (Fig. 3). The
necessity for such a combination was recently highlighted
by treatment of hES-derived DE cells with Noggin in the
absence of RA; this blocked the expression of liver mark-
ers, but did not generate PDX1
 cells (20,23). This require-
ment for combining RA treatment with BMP antagonism
FIG. 1. Overview of transcription factors (TFs) expression during -cell development. Expression of different combinations of TFs determines
the sequential lineage segregation in the developing pancreas. Not only are the combinations of TFs important, but the expression level of a
particular TF is known to guide differentiation as well. Low protein levels are indicated in parentheses. The most relevant TFs that are landmarks
for the selection of each stage/lineage are shown.
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signaling was shown to activate BMP expression in several
in vivo and in vitro systems including embryonal carci-
noma cells and differentiating mouse embryoid bodies
(34–36). It is not yet clear whether this inductive effect on
BMP also occurs during hES cell differentiation. Neverthe-
less, considering the in vivo function of BMP signaling in
the midgut endoderm, it appears reasonable that both
retinoid signaling and BMP antagonism were required in
these studies for strong induction of a pancreatic fate from
the DE cells while preventing hepatic differentiation. How-
ever, it is likely that the effect of RA is context-dependent
because when applied on hES-derived DE cells cultured at
low density, it resulted in the inhibition of Smad 1/5/8
phosphorylation (23). It remains to be elucidated whether
this later effect represents an artifact of in vitro culture or
a speciﬁc retinoid effect at the single cell level.
Other studies made use of RA combined with FGF
ligands (FGF4, FGF7, FGF10) or of Noggin combined with
FGF2 and EGF to induce pancreatic cells albeit at a lower
efﬁciency than for combined Noggin and RA (Table 3)
(13,14,16,17,19,23). Our unpublished observations suggest
that FGF signals favor hepatic gene expression in the
absence of BMP antagonism, but the addition of FGF
ligands together with BMP antagonism (Noggin) and RA
enhances pancreatic gene expression. Furthermore, the
induction of PDX1
 cells by combined Noggin and RA
requires at least a basal level of FGF activity (via the
extracellular signal–regulated kinase/mitogen-activated
protein kinase [ERK/MAPK] pathway [Fig. 3]) given that
the addition of the MAPK-inhibitor U1026 prevented pan-
creatic cell differentiation (20). Because RA is known to
act synergistically with FGF signaling during endoderm
patterning, supplemented FGF can be seen as an enhanc-
ing factor in protocols that already integrate Noggin and
RA (13,14,19). This view might resolve the nature of
factors X suggested as involved in the indirect effects of
RA in Xenopus dorsal endoderm (37). It was recently
suggested that in the presence of FGF7, RA can efﬁciently
induce PDX1 progenitors from hES-derived DE cells
seeded at low density (5–50,000 cells/cm
2) and that this
effect is paralleled by inhibition of Smad1/5/8 phosphory-
lation, therefore recapitulating BMP antagonism described
above (23).
Recent analysis of the signaling network during early
liver and pancreas development in 3–6 somites-stage
mouse embryos further indicated that inhibition of the
activin signaling signiﬁcantly increases the proportion of
cells fated toward PDX1 expression. These ﬁndings there-
fore suggest that the addition of activin inhibitors to the
above-mentioned cocktails might still boost the occur-
rence of PDX1
 cells in hES cell cultures (13,24).
Despite the fact that combining BMP antagonism with
retinoid signaling efﬁciently generates PDX1
 pancreatic
progenitors from hES-derived deﬁnitive endoderm, the
requirement for hedgehog antagonism with cyclopamine
during pancreas induction from these cells has not been
clariﬁed by these studies. The initial report by D’Amour et
al. (18) indicated the necessity to antagonize hedgehog
signaling that is indeed activated during ES cell differen-
tiation, and it was shown to also play a negative role ex
vivo by limiting endocrine and exocrine genes expression
in embryonic (E12.5) mouse pancreatic explants (38,39).
However, additional studies using Noggin, FGF ligands,
TABLE 3
Derivation of PDX1
 progenitors from hES cells
References DE induction Pancreas induction Differentiation Key features
D’Amour (2006) ActA  Wnt3a; ActA 
FBS
FGF10  Cyclo (4d);
FGF10  Cyclo  RA
(4d)
DAPT  Ex4; IGF1 
HGF  Ex4
7% INS
 cells, double 
endocrine cells; no glucose
response
Johannesson
(2009)
ActA  Wnt3a; ActA 
FBS
FGF4  RA (/ Cyclo) — 32% PDX1
 cells, very low INS
expression
Cai (2009) ActA; ActA  ITS (DE replating on 3T3)
FGF7  RA (6d)
HGF  Ex4  NA
(6d)
90% PDX1
; co-expression
FOXA2, HNF1b, HNF4a,
HNF6, NKX6.1; some INS

cells
Jiang (2007) ActA  NaBut (7d) EGF  bFGF  NG (14d);
EGF  NG (7d)
NA  IGF2 (5d); NA
(2d)
EBs after DE induction; budding
PDX1
 INS
 clusters; 3D is
better
Kroon (2008) ActA  Wnt3a; ActA 
FBS
FGF7 (4d); NG  RA 
FGF7 (4d)
Transplantation in
immunodeﬁcient
mice
Endocrine cells in grafts,
glucose response in vivo at 3
months, protection from STZ
effect
Vallier (2009) ActA  BMP4  bFGF
(3d)
NG  RA  FGF10 
SB431542 (6d)
— PDX1
 clusters, culture in
feeder-free settings
Zhang (2009) ActA  Wortmanin
(4d)
NG  RA  FGF7 (4d);
EGF (5d)
bFGF  Ex4  BMP4
 NA  ITS (7d)
20% PDX1
, 25% INS
, low
glucose response, ITS issue
not addressed
Mfopou (2010) ActA  Wnt3a; ActA 
FBS
NG  RA  Cyclo (8d);
FGF10  Ex4 
Compound E (4d)
NA  Ex4  IGF1 
BMP4
50–80% PDX1
 in 4 hES lines,
co-expression FOXA2, SOX9,
HNF1b, HNF6, NKX6.1, low
PTF1a. Some INS
 cells
Recent models of pancreas differentiation from hES cells integrate BMP antagonism and retinoid signaling early after deﬁnitive endoderm
induction. This allows for concomitant hepatic blockade and pancreas induction from deﬁnitive endoderm cells. Cyclo, cyclopamine;
DAPT, N-[N-(3,5-Diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (gamma secretase inhibitor); EBs, embryoid bodies; Ex4,
exendin-4; FBS, fetal bovine serum; ITS, insulin selenium transferring supplement; NA, nicotinamide; NaBut, sodium butyrate; NG, Noggin;
STZ, streptozotocin; 3D, three dimensional. The text in bold marks protocol with combination of NG and RA.
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PDX1
 cells without the use of hedgehog inhibitors
(14,17,19,23). Owing to the previously described increase
in the expression of hedgehog ligands and effectors upon
DE induction, we added cyclopamine to the combination
of Noggin and RA in our experimental setup, but it remains
unclear whether this was mandatory for the efﬁcient
differentiation of PDX1
 cells that we observed (20,38,39).
While waiting for conclusive data on this issue, we speculate
that supplementation of hedgehog antagonists would be-
come obsolete in settings where combined Noggin and RA
treatment of DE cells essentially induces a “true pancreatic
endoderm” cell type, which is normally devoid of hedgehog
activity. Gli1 transcripts proﬁling in cells treated with Noggin
and RA combination would help to clarify this issue.
Ampliﬁcation of early pancreas progenitors by FGF
signaling. Pancreatic progenitor cells are characterized
by their expression of a subset of transcription factors. For
instance, the combined expression of PDX1, FOXA2,
SOX9, HNF6, NKX6.1, and PTF1a (Fig. 3) deﬁne the
multipotent pancreas progenitor (9,33). In the endoderm,
the last two transcription factors are more speciﬁc to the
FOXA2 ALBUMIN FOXA2 ALBUMIN
PDX1 PDX1 DNA 
NKX6.1 DNA SOX9  PDX1
AB
C
D E
FIG. 2. Expression of pancreas-related transcription factors in hES-derived DE progenies treated with Noggin, RA, and cyclopamine. FOXA2 and
albumin expression in control cultures (A) and following treatment with Noggin, RA, and cyclopamine (B). Note the major increase in FOXA2 and
loss of ALB-expressing cells. C: Large clusters of PDX1
 progenitors are detected, representing 50–80% cells. D: Several NKX6.1
 cells are also
detectable, the majority of which express lower levels of PDX1 (not shown). E: Co-expression of PDX1 and SOX9 transcription factors in
differentiated cells. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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also detected in the adjacent duodenum, stomach, and
liver. Following the induction of pancreas progenitor cells
from hES-derived DE cells, PDX1 co-expression with
FOXA2, SOX9, and HNF6 was demonstrated in a context
where hepatic (AFP, ALB) and intestinal (CDX1, CDX2)
markers were not induced or only minimally induced (Fig.
2) (14,17,20). However, none of the above-mentioned
studies have assessed the expression of all the six tran-
scription factors by the pancreatic progenitors obtained
from hES cells. More speciﬁcally, demonstration of PTF1a
expression has remained elusive until now, possibly owing
to the lack of an optimal antibody against this protein. The
same holds true for NGN3, which has been detected at the
protein level in only few studies. In our experimental
setup, PTF1a transcripts were detected only at low levels,
whereas a signiﬁcant emergence of NKX6.1-positive cells
was denoted. Nevertheless, when combined with the dem-
onstration of INS and PDX1 co-expression at later stages,
these ﬁndings point toward the pancreatic nature of the
differentiated PDX1
 cells. Additional efforts are required
to obtain their efﬁcient differentiation toward pancreatic
endocrine cells in vitro (Table 3) (14,20).
During pancreas development, the PDX1
 progenitor
cells are ampliﬁed thanks to signals emanating from the
pancreatic mesenchyme. FGF10 controls this mesenchy-
mal-to-epithelial interaction, and its over-expression be-
yond the competence window (E11.5–E13.5 in the mouse)
signiﬁcantly induces progenitor cell proliferation and ar-
rests their terminal differentiation (40,41). This signaling
operates via activation of the Notch pathway, which
temporally prevents progenitor differentiation toward the
endocrine or exocrine fates (42). In agreement with these,
FGF10 or EGF supplementation induces the proliferation of
hES-derived PDX1
 cells, suggesting the contribution of
ERK/MAPK and AKT activation in this effect (14,16,20).
Furthermore, before the proliferation step, establishment
of the PDX1
 progenitors from hES-derived deﬁnitive
endoderm was also shown to be highly dependent on ERK/
MAPK signaling and possibly mediated by FGF2 (20,43).
Prospects for further endocrine differentiation of
hES cell–derived pancreatic progenitors. The initia-
tion of endocrine differentiation from the PDX1
 progen-
itors relies on the activation of NGN3 expression, which
should be paralleled or preceded by downregulation of
Notch activity and further sustained by additional induc-
tion of PAX6 (Fig. 1) (44,45). Although the transcription
factors cascade regulating pancreatic endocrine differen-
tiation has been largely explored, to date the instructive
extracellular signals that trigger their coordinated expres-
sion remain elusive. To this end, there is a growing list of
proposed growth factors and chemicals whose effects will
need to be extensively assessed in the endocrine commit-
ment and maturation of PDX1
 progenitors obtained in
vitro from hES-derived DE cells. These include but are not
limited to Wortmannin and LY294002 that are PI3K inhib-
itors (46), VEGF (4,47), RA (26), Conophylline (48), Wnt,
and Hedgehog ligands (49,50), and antagonists of the
Notch pathway such as gamma secretase inhibitors, Notch
FIG. 3. Molecular pathways involved in pancreas and liver differentiation from hES cells. Four main pathways regulate the early stages of pancreas
differentiation from deﬁnitive endoderm and control the acquisition of hepatic vs. pancreatic fate. Hedgehog signaling is well characterized as a potent
inhibitor of pancreatic initiation (a) that is expressed in the hepatic domain (b) under the inﬂuence of FGF signaling. It functions in the establishment
of organ domains. This pathway can be blocked by treatment with the alkaloid cyclopamine. Retinoic acid is expressed in the developing pancreas and
participates in the induction of PDX1 expression (c). It is also suggested to contribute to hepatic gene expression to a certain degree (d). An inhibitory
effect of retinoic acid on Smad1-5-8 phosphorylation (e) was demonstrated on hES-derived deﬁnitive endoderm seeded at low density, which contrasts
with the early studies indicating activation of BMP signaling by retinoic acid. BMP is well described as an inhibitor of early pancreas development (f)
in contrast to its requirement for hepatic initiation (g). This potent inhibitory effect at early stages gets reverted afterward and pancreatic progenitors
require BMP signaling (f). The inhibition of BMP signaling in the pancreatic domain is under the control of Noggin (h). As for BMP pathway, FGF
signaling via ERK/MAPK also controls early pancreas induction with high concentration being inhibitory (i) whereas low concentrations are required
(j). In late stages, FGF plays in the proliferation of pancreas progenitors (j). On the contrary, this pathway represents an ampliﬁcation signal (h) for
the ALB
AFP
 hepatoblast. The markers displayed in the progenitors recall the current status of protein detection from differentiated hES cells.
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factors important, but their timely combination will also
be of consideration given the demonstration of a compe-
tence window for endocrine patterning beyond which the
endocrine differentiation arrest becomes irreversible (41).
For instance in our experimental setup (Table 3), FGF10
was supplemented for controlling PDX1
 cell proliferation
together with a gamma secretase inhibitor (Compound E)
for Notch antagonism in view of endocrine induction (20).
Considering the above-mentioned crosstalk between
FGF10 and Notch activity in the proliferation of the
PDX1
 progenitors, such a protocol therefore included
two phenomenas that were actually antagonistic. This
issue might explain the very limited progression toward
endocrine cells that we obtained, a hypothesis that will
need further evaluation by dissociating FGF10 treatment
from Notch inhibition in this protocol.
The next step after endocrine commitment will be the
further endocrine differentiation and maturation by use of
old and new players such as betacellulin, activin, exendin-4,
insulin-like growth factor, HGF, nicotinamide, bone morpho-
genetic protein, FGF, and RA (14,16,18,20,26,28). Similarly,
three-dimensional cultures will merit further investigation
in order to mimic the actual environment of the -cells in
islets as was recently described in differentiating hES cells
(16). Some of these factors have been used singly or in
combination on PDX1
 progenitors generated from hES
cells. Because of the complex nature of pancreatic endo-
crine differentiation, which is presently not yet elucidated,
the generation of mature and functional -cells has not
been efﬁciently achieved in vitro. The demonstration of
human-speciﬁc –cell functions in animal models follow-
ing transplantation of pancreatic progenitors derived from
hES cells (19,32,51) underscores this gap in our current
knowledge. Based on these data, it has been proposed that
diabetic patients could be grafted with pancreatic progen-
itors derived from hES cells, eliminating the need for
ﬁnding the efﬁcient strategy for terminal differentiation in
vitro. However, this approach would be hampered by
teratoma formation from cells that were not fully differ-
entiated at the time of transplantation (see below).
Molecular beacons for cell selection. Although the
differentiation of speciﬁc cell types such as pancreatic
cells can be established through their characterization
with several markers, it remains obvious that no protocol
currently offers a factual conversion of all cultured stem
cells to the desired phenotype. Therefore, the possibility
exists that other cell types or even multi- or pluripotent
cells might be transplanted to the diabetic recipients,
which raises safety issues. Indeed, despite the fact that
functional -cells developed in vivo after transplantation
of hES-derived pancreatic cell preparations, teratoma for-
mation was also observed in at least 15% of grafts
(19,51,52). Several tools have been investigated in order to
select out the undifferentiated cells that express surface
markers (SSEA4, SSEA3, TRA-1–60, TRA-1–81) or to spe-
ciﬁcally isolate the desired cell type (cell-trapping) that
have been modiﬁed to express an antibiotic resistance
gene, a ﬂuorescent or a bioluminescent reporter under
CK19, PDX1, or INS promoter (53–55). Whereas these
techniques would allow for the selection of differentiated
-cells up to purity, transplantation of such cells is pres-
ently not approved given the genotoxic, the mutagenic,
and the oncogenic risks associated with transgenic ap-
proaches. New transgenic designs are currently under
development to speciﬁcally address these issues.
Concluding remarks. The in vitro differentiation of func-
tional -cells from human pluripotent cells (hES and iPS)
represents a major challenge for diabetes cell therapy in
the future. Progress toward this goal already encompasses
the efﬁcient generation of deﬁnitive endoderm and PDX1-
expressing pancreas progenitors. The recent successful
studies indicate that the differentiation of PDX1
 progen-
itors concomitantly requires at least two events after DE
establishment in order to mimic the in vivo situation:
blockade of hepatic induction by BMP antagonism and
induction of pancreas progenitors by retinoid signaling
(Fig. 3). Optimization of this step might still prove beneﬁ-
cial in order to unravel the role of FGF and hedgehog
modulation and in order to deﬁnitely establish cells that
undoubtedly show combined expression of the major
transcription factors recognized for the multipotent pan-
creas progenitor, namely PDX1, PTF1a, and NKX6.1. In
addition, the recently described temporal shift in the
requirement for BMP antagonism to a need for BMP
signaling during mouse pancreas development will merit
implementation in hES cell differentiation. Despite the
latest data indicating differentiation of the PDX1
 progen-
itors into insulin/C-peptide
 cells, we believe that addi-
tional work is needed for an optimal in vitro control of the
progression toward NGN3-expressing endocrine progenitor
cells and for the maturation of glucose-sensing and insulin-
secretion functions in the -like cells. A step forward toward
these goals will certainly shorten the time frame for achiev-
ing our objective of using hES cells as alternative sources of
functioning -cells in diabetes cell therapy.
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